EMD Serono's experience and scientific discoveries in MS date back more than 20 years. We have an ongoing commitment to improving the entire patient experience. To this end, we offer delivery devices for our therapeutic products as well as comprehensive patient education resources.
It is the people living with MS or those who will be diagnosed with MS, their caregivers and healthcare providers who have been our catalyst and inspiration to continue innovating, collaborating and advocating.
With our history in neurology and leadership as a science-driven organization, we are deepening our commitment to people with neurological and immunological diseases by researching and innovating new therapeutic options that can make a real difference in their lives.
The development and discovery of innovative treatments for MS remains a top focus for our scientists. Our pipeline has potential to impact treatment across multiple immunological conditions, including MS, rheumatoid arthritis and systemic lupus erythematosus.
We are also investigating new treatments for immunological conditions such as psoriasis, osteoarthritis and systemic sclerosis with interstitial lung disease.
Our research and development led to the introduction of
Rebif® (interferon beta-1a), one of the early disease-modifying therapies for people living with MS. Even today, after being available for more than 15 years, Rebif remains an important therapy for people with relapsing forms of MS.
MS LifeLines Ambassadors pictured above are sponsored by EMD Serono, Inc.
Rebif can cause serious side effects including the following: behavioral health problems including depression and suicidal thoughts, serious allergic and skin reactions, injection site skin damage, liver problems or worsening of liver problems including liver failure. Symptoms may include changes in urine, stool, and skin color, tiredness, confusion, and bleeding. Rebif can also cause low red and white blood cell and platelet counts. Symptoms may include infections, problems with bleeding and bruising.
For complete product details, please refer to the full Prescribing Information and Medication Guide for full disclosure.